Learnings from IO combinations and where we’re headed

Lessons learned from recent failure and a look at where a few new developments might be coming from...

August 23, 2018

Exploring Gamida Cell with Dr Julian Adams

A look at what Gamida Cell, an up and coming cellular and innate immunotherapy company are up to...

March 15, 2018

Targeting NK cells effectively in AML

A look at targeting NK cells with immune agonists, cytokines and adoptive cell therapies

March 14, 2018

A look at NK cells – an interview with Dr Michael Caligiuri

A look at the history of NK cell development and where we're going in future with this IO approach

March 7, 2018

Challenges and Opportunities with NK cells for cancer therapeutics

Our latest primer explores NK cells and their role in oncology R&D - it's an up and coming area

March 5, 2018

Update on cytokines as novel cancer immunotherapy

A look at innate approaches to stimulating the immune system including IL-15 agonists

February 21, 2018

Pathways to success targeting CD47-SIRPα

Insights from researchers in the CD47 niche - what do they really think?

February 20, 2018

A look at the controversial CD47-SIRPα landscape

A look at the players in controversial CD47-SIRPα landscape

February 15, 2018

Flying high with the controversial CD47-SIRPα pathway in cancer

A look at biology behind targeting CD47 in cancer and some of the controversies plaguing the space

February 7, 2018

A look at an up and coming west coast biotech

A look at the pipeline of the up and coming Seattle biotech, Alpine Immune Sciences

January 22, 2018

Syros CEO Nancy Simonian looks forward to an exciting 2018

Interview with Syros Pharma CEO Dr Nancy Simonian

January 9, 2018

A competitive threat to CAR T cell therapy in aggressive lymphoma

New approaches that enter a market unexpectedly can disrupt the status quo and push out more severe therapies to later lines of treatment

January 3, 2018

The Future of Multiple Myeloma

A look at key pipeline developments in multiple myeloma through the lens of a global expert in the field

January 2, 2018

The science behind the venetoclax clinical trial strategy

Where is the venetoclax BCL-2 program going in hematologic malignancies?

December 18, 2017

ASH17 masterclass with Dr John Leonard on lymphomas

An interview with Dr John Leonard exploring his thoughts on some of the key lymphoma data at #ASH17

December 14, 2017

ASH17 Will MURANO impact the CLL landscape?

As we see new readouts emerge with different doublets and triplets in CLL, how will they impact the treatment landscape?

December 13, 2017
Snow at GWCC

Commentary on ASH17 Day 2 in Atlanta

Commentary on Sunday at 2017 ASH annual meeting in Atlanta

December 10, 2017

ASH17 – Day 1 Highlights and Lowlights

A look at some of the sessions and learnings from the first day at ASH 2017

December 9, 2017

ASH17 CAR T cell therapy Preview

A look at what's hot in CAR T cell therapies at #ASH17

December 4, 2017

Top 10 #ASH17 abstracts to watch out for

The Mav's key oral abstracts to follow at #ASH17 -- warning this list includes quirky selections!

November 30, 2017

ASH Preview 2 – Developmental Therapeutics

A look at a selection of promising Developmental Therapeutics abstracts from ASH17 - what's in store this year?

November 29, 2017

ASH17 Preview of emerging therapies for Aggressive Lymphomas

A look at up and coming emerging therapies in the DLBCL space

November 1, 2017